Skip to main content

Table 2 Study population characteristics stratified by a fourteen-day-time-to-surgery

From: Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma

A. Baseline characteristics

Characteristics (n = 168)

 ≤ 14 days

 > 14 days

p

n

59

106

 

Male (%)

38 (64.4)

58 (54.7)

0.334

Age (median [IQR])

65.00 [57.00, 69.50]

67 [59, 73]

0.109

BMI (median [IQR])

25.52 [23.20, 29.49]

25.10 [22.50, 28.33]

0.474

Performance status (%)

  

0.747

 0

23 (65.7)

47 (71.2)

 

 1

10 (28.6)

17 (25.8)

 

 2

2 (5.7)

2 (3.0)

 

Jaundice (%)

47 (79.7)

67 (63.2)

0.044*

Diagnosed during hospital stay (%)

30 (50.8)

45 (42.5)

0.382

Tumor location (%)

  

0.3

 Head

51 (87.9)

82 (78.1)

 

 Body

3 (5.2)

10 (9.5)

 

 Tail

4 (6.9)

13 (12.4)

 

Lymphadenopathy at imaging (%)

9 (21.4)

18 (20.2)

1

Endoscopic biliary drainage (%)

10 (20.8)

46 (65.7)

 < 0.001*

Radiological biliary drainage (%)

1 (2.1)

5 (7.1)

0.422

Total bilirubin (µmol/L) (median [IQR])

173.00 [74.25, 304.50]

21.00 [8.00, 84.75]

 < 0.001*

Conjugated bilirubin (µmol/L) (median [IQR])

140.50 [60.50, 236.25]

22.00 [4.00, 76.50]

 < 0.001*

Neutrophil-to-lymphocyte ratio (median [IQR])

2.67 [2.06, 4.09]

2.68 [1.92, 3.52]

0.223

B. Surgery procedure, histopathological, and follow up characteristics stratified on a 14 days-time to surgery n total population; IQR interquartile range; NA not available; *statistical significance

Characteristics (n = 168)

 ≤ 14 days

 > 14 days

p

n

59

106

 

Type of resection (%)

  

0.497

Duodenopancreatectomy

50 (84.7)

79 (74.5)

 

Splenopancreatectomy

7 (11.9)

20 (18.9)

 

Left pancreatectomy

1 (1.7)

3 (2.8)

 

Total pancreatectomy

1 (1.7)

4 (3.8)

 

Vein resection (%)

16 (27.1)

52 (49.1)

0.01*

Organ resection (%)

4 (6.8)

6 (5.7)

1

T (%)

  

0.375

 1

0 (0.0)

3 (2.9)

 

 2

6 (10.2)

18 (17.3)

 

 3

49 (83.1)

77 (74.0)

 

 4

4 (6.8)

5 (4.8)

 

 x

0 (0.0)

1 (1.0)

 

N (%)

  

0.488

 0

11 (18.6)

26 (24.8)

 

 1

48 (81.4)

78 (74.3)

 

 x

0 (0.0)

1 (1.0)

 

M (%)

  

0.111

 0

53 (89.8)

101 (96.2)

 

 1

6 (10.2)

3 (2.9)

 

 x

0 (0.0)

1 (1.0)

 

Invaded/sampled lymph nodes (median [IQR])

0.06 [0.00, 0.15]

0.10 [0.00, 0.20]

0.403

Resection status = 1 (%)

23 (39.0)

38 (36.2)

0.852

Microscopic vascular thrombosis (%)

38 (84.4)

64 (79.0)

0.612

Perineural invasion (%)

50 (92.6)

86 (93.5)

1

Hemorrhage (%)

10 (25.6)

11 (16.2)

0.351

Fistula (%)

12 (31.6)

28 (41.2)

0.442

Severe complications (%)

15 (25.4)

26 (24.5)

1

Length of stay (days) (median [IQR])

21.00 [15.00, 28.00]

19.00 [13.25, 25.00]

0.416

Adjuvant chemotherapy (%)

52 (91.2)

87 (82.9)

0.222

Number of chemotherapy cycles (median [IQR])

6.00 [5.50, 6.00]

6.00 [5.33, 6.00]

0.710

Adjuvant radiotherapy (%)

4 (7.0)

9 (8.6)

1.000

Local disease recurrence (%)

0 (0)

6 (5.7)

 

Distant disease recurrence (%)

48 (81.3)

72 (74.5)

0.761

Lymph node recurrence (%)

12 (35.3)

24 (43.6)

0.578

Liver recurrence (%)

21 (61.8)

24 (43.6)

0.149

Peritoneal recurrence (%)

5 (14.7)

10 (18.2)

0.893

Other (%)

10 (29.4)

14 (25.5)

0.871

Death (%)

41 (69.5)

70 (66.0)

0.779

Time from surgery to adjuvant chemotherapy (days) (median [IQR])

55.00 [43.50, 74.50]

54.00 [42.75, 63.00]

0.543

  1. n total population; IQR interquartile range; NA not available
  2. *Statistical significance according to Mann–Whitney test (nonnormal continuous variables) or Chi-square test (categorical variable)